TEL AVIV, Israel – (NewMediaWire) – November 15, 2021 – Leafreport.com (“Leafreport” or the “Company”), the CBD industry’s peer-reviewed watchdog website, announced today the results from a comprehensive review of hemp-derived cannabigerol (CBG) products. Aimed at understanding if CBG products provide the advertised amount of CBG, the findings found that over half (52.6%) of the products sent for testing contained the wrong amount of CBG. These products were off from the labeled CBG strength by anywhere from 10.4% to 64.7%.
Among the findings, the Company found that out of 24 products advertised to carry a specific amount of CBG and CBD, only 4 (17%) matched both the CBD and CBG labels. In addition, seven products (29%) were accurate for CBG but not CBD, 8 (33%) were accurate for CBD but not CBG, and 5 (21%) were inaccurate for both. All 15 of the products advertised to contain broad or full-spectrum CBD had the right type of extract, a first in the Company’s report.
For this report, Leafrepprt purchased 38 CBG products and sent them to SC Labs, a reputable cannabis testing lab, for third-party testing. Leafreport’s experts compared the test results to the amount of CBG and other cannabinoids listed on the product label and description.
This report is one of many completed by Leafreport aimed at informing consumers about various aspects of the CBD industry. The Company has previously sent CBD products to the cannabis testing lab Canalysis to see if they contained the advertised levels of CBD, among other tests. These reports include recent deep-dives into Delta-8, topicals, edibles, beverages, and more.